blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2200634

EP2200634 - TARGETED INTERFERON DEMONSTRATES POTENT APOPTOTIC AND ANTI-TUMOR ACTIVITIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.12.2015
Database last updated on 14.05.2024
Most recent event   Tooltip20.07.2018Lapse of the patent in a contracting state
New state(s): PT		published on 22.08.2018  [2018/34]
Applicant(s)For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607 / US
[2015/07]
Former [2010/26]For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607-5200 / US
Inventor(s)01 / MORRISON, Sherie, L.
258 Denslow Avenue
Los Angeles California 90049 / US
02 / HUANG, Tzu-Hsuan
7009 Almeda Road
Apt. 1926
Houston, Texas 77054 / US
03 / XUAN, Caiyun
11811 Venice Boulevard
Apt. 239
Los Angeles, California 90066 / US
 [2015/07]
Former [2010/26]01 / MORRISON, Sherie, L.
258 Denslow Avenue
Los Angeles California 90049 / US
02 / HUANG, Tzu-Hsuan
7009 Almeda Road Apt. 1926
Houston, Texas 77054 / US
03 / XUAN, Caiyun
11811 Venice Boulevard Apt. 239
Los Angeles, California 90066 / US
Representative(s)Turner, Rhiannon Rosalind, et al
Greaves Brewster LLP
Copa House
Station Road
Cheddar, BS27 3AH / GB
[2015/07]
Former [2010/28]Turner, Rhiannon Rosalind, et al
Greaves Brewster LLP Indigo House Cheddar Business Park
Cheddar, Somerset BS27 3EB / GB
Former [2010/26]Turner, Rhiannon Rosalind
Greaves Brewster LLP Indigo House Cheddar Business Park
Cheddar, Somerset BS27 3EB / GB
Application number, filing date08831632.819.09.2008
[2010/26]
WO2008US77074
Priority number, dateUS20070994717P21.09.2007         Original published format: US 994717 P
[2010/26]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009039409
Date:26.03.2009
Language:EN
[2009/13]
Type: A1 Application with search report 
No.:EP2200634
Date:30.06.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 26.03.2009 takes the place of the publication of the European patent application.
[2010/26]
Type: B1 Patent specification 
No.:EP2200634
Date:11.02.2015
Language:EN
[2015/07]
Search report(s)International search report - published on:US26.03.2009
(Supplementary) European search report - dispatched on:EP26.04.2012
ClassificationIPC:A61K38/21, A61K47/48, C07K16/32, A61P35/00, C12N15/62
[2012/20]
CPC:
A61K38/212 (EP,KR,US); A61K9/0019 (US); A61K38/215 (EP,KR,US);
A61K39/395 (KR); A61K47/6813 (EP,KR,US); A61K47/6851 (EP,KR,US);
A61K47/6855 (EP,KR,US); A61K47/6875 (EP,US); A61P35/00 (EP);
A61P35/02 (EP); A61P35/04 (EP); C07K14/555 (EP,KR,US);
C07K14/56 (KR,US); C07K14/565 (KR,US); C07K16/2863 (KR,US);
C07K16/2887 (EP,US); C07K16/32 (EP,KR,US); A61K2039/505 (EP,US);
A61K38/00 (EP,US); C07K2317/24 (US); C07K2317/622 (EP,US);
C07K2319/33 (EP,US) (-)
Former IPC [2010/26]A61K38/21
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/26]
TitleGerman:INTERFERON-TARGET ZEIGT STARKE APOPTOTISCHE UND ANTITUMORALE WIRKUNGEN[2010/26]
English:TARGETED INTERFERON DEMONSTRATES POTENT APOPTOTIC AND ANTI-TUMOR ACTIVITIES[2010/26]
French:INTERFÉRON CIBLÉ MANIFESTANT DES ACTIVITÉS APOPTOTIQUES ET ANTI-TUMORALES PUISSANTES[2010/26]
Entry into regional phase19.04.2010National basic fee paid 
19.04.2010Search fee paid 
19.04.2010Designation fee(s) paid 
19.04.2010Examination fee paid 
Examination procedure19.04.2010Examination requested  [2010/26]
16.11.2012Amendment by applicant (claims and/or description)
08.02.2013Despatch of a communication from the examining division (Time limit: M06)
09.08.2013Reply to a communication from the examining division
10.02.2014Cancellation of oral proceeding that was planned for 13.03.2014
04.03.2014Communication of intention to grant the patent
13.03.2014Date of oral proceedings (cancelled)
08.07.2014Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
02.10.2014Communication of intention to grant the patent
22.12.2014Fee for grant paid
22.12.2014Fee for publishing/printing paid
22.12.2014Receipt of the translation of the claim(s)
Divisional application(s)EP14180412.0  / EP2853267
EP16195608.1  / EP3150218
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.02.2013
Opposition(s)12.11.2015No opposition filed within time limit [2016/03]
Fees paidRenewal fee
27.09.2010Renewal fee patent year 03
26.09.2011Renewal fee patent year 04
25.09.2012Renewal fee patent year 05
27.09.2013Renewal fee patent year 06
29.09.2014Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.09.2008
AT11.02.2015
BE11.02.2015
BG11.02.2015
CY11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
FI11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
MC11.02.2015
MT11.02.2015
NL11.02.2015
PL11.02.2015
PT11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
TR11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
LU19.09.2015
[2018/34]
Former [2017/39]HU19.09.2008
AT11.02.2015
BE11.02.2015
BG11.02.2015
CY11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
FI11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
MC11.02.2015
MT11.02.2015
NL11.02.2015
PL11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
TR11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
LU19.09.2015
Former [2017/21]AT11.02.2015
BE11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
FI11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
MC11.02.2015
MT11.02.2015
NL11.02.2015
PL11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
LU19.09.2015
Former [2016/24]AT11.02.2015
BE11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
FI11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
MC11.02.2015
NL11.02.2015
PL11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
LU19.09.2015
Former [2016/23]AT11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
FI11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
MC11.02.2015
NL11.02.2015
PL11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
LU19.09.2015
Former [2016/21]AT11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
FI11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
NL11.02.2015
PL11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
LU19.09.2015
Former [2016/12]AT11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
FI11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
NL11.02.2015
PL11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
Former [2015/50]AT11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
FI11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
NL11.02.2015
PL11.02.2015
RO11.02.2015
SK11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
Former [2015/49]AT11.02.2015
CZ11.02.2015
DK11.02.2015
EE11.02.2015
FI11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
NL11.02.2015
RO11.02.2015
SK11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
Former [2015/39]AT11.02.2015
FI11.02.2015
HR11.02.2015
LT11.02.2015
LV11.02.2015
NL11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
Former [2015/38]AT11.02.2015
FI11.02.2015
HR11.02.2015
LT11.02.2015
NO11.05.2015
GR12.05.2015
IS11.06.2015
Former [2015/37]FI11.02.2015
HR11.02.2015
LT11.02.2015
NO11.05.2015
GR12.05.2015
Former [2015/36]FI11.02.2015
HR11.02.2015
LT11.02.2015
NO11.05.2015
Former [2015/35]LT11.02.2015
NO11.05.2015
Documents cited:Search[XI]WO0197844  (IDEC PHARMA CORP [US]) [X] 1-12,14-16 * claims 1, 2, 3, 4, 6-17 * * examples 1-3 * * the whole document * [I] 1-16;
 [XY]WO03080106  (UNIV CALIFORNIA [US], et al) [X] 1-5,7,8,10,14-16 * the whole document * * claims 1, 5, 7 * * page 5, paragraph l * * page 7, paragraph 2 * * page 18, paragraph l * * page 20, paragraph 3 - page 23, paragraph 3 * * example I * [Y] 1-16;
 [XY]US2005008649  (SHIN SEUNG-UON [US], et al) [X] 1-5,7,8,10,14-16 * claims 1, 2, 12, 13, 14, 15, 32, 33, 46, 58 * * examples 1-12 * * page 9, column r, paragraph 102 * * page 11, column l, paragraph 117 * [Y] 1-16;
 [XPI]  - HUANG TZU-HSUAN ET AL, "Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 NOV 2007 LNKD- PUBMED:17982079, (20071115), vol. 179, no. 10, ISSN 0022-1767, pages 6881 - 6888, XP009158288 [XP] 1-8,10,14-16 * the whole document * [I] 1-16

DOI:   http://dx.doi.org/10.4049/jimmunol.179.10.6881
 [XI]  - HUANG ET AL, "Fusion of anti-HER2/neu with inflammatory cytokines IFN-alpha and TNF-alpha results in molecules that elicit an anti-tumor response or potentiate wound healing", DISSERTATION,, (20060101), pages 1 - 120, XP009158273 [X] 1-8,10,14-16 * the whole document * * page xii - page xiii * * page 15 * * page 19, paragraph 1 * * page 114, paragraph 2 - page 115, paragraph 1 * [I] 1-16
 [XY]  - SCHRAMA D ET AL, "Antibody targeted drugs as cancer therapeutics", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 5, no. 2, doi:10.1038/NRD1957, ISSN 1474-1776, (20060201), pages 147 - 159, (20060120), XP002566323 [X] 1,14-16 * the whole document * * page 152, column r, paragraph 3 * [Y] 1-16

DOI:   http://dx.doi.org/10.1038/nrd1957
 [Y]  - JAIN ET AL, "Engineering antibodies for clinical applications", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (20070701), vol. 25, no. 7, ISSN 0167-7799, pages 307 - 316, XP022116341 [Y] 1-16 * the whole document * * page 313; table 1 * * page 313 - page 314 *
 [Y]  - HELGUERA GUSTAVO ET AL, "Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, (20060401), vol. 5, no. 4, doi:10.1158/1535-7163.MCT-05-0488, ISSN 1535-7163, pages 1029 - 1040, XP002490883 [Y] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-05-0488
 [Y]  - BOSLY A, "Place de l association de l anticorps monoclonal anti-CD20 avec les agents immunomodulateurs = Role of anti-CD20 monoclonal antibody in association with immunomodulatory agents", PATHOLOGIE ET BIOLOGIE, L'EXPANSION SCIENTIFIQUE FRANCAISE, PARIS, FR, vol. 52, no. 1, doi:10.1016/S0369-8114(03)00051-8, ISSN 0369-8114, (20040101), pages 39 - 42, (20040128), XP009158287 [Y] 1-16 * the whole document * * page 40, paragraph 1. *

DOI:   http://dx.doi.org/10.1016/S0369-8114(03)00051-8
 [T]  - XUAN CAIYUN ET AL, "Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.", BLOOD 8 APR 2010 LNKD- PUBMED:20139095, (20100408), vol. 115, no. 14, ISSN 1528-0020, pages 2864 - 2871, XP002673645 [T] * the whole document *

DOI:   http://dx.doi.org/10.1182/BLOOD-2009-10-250555
International search[X]US6428788  (DEBINSKI WALDEMAR [US], et al);
 [A]US2004005647  (DENARDO SALLY JOAN [US], et al);
 [A]US2005079154  (YARKONI SHAI [IL], et al);
 [A]US2005232931  (MA JING [US], et al);
 [Y]US2006263368  (ROSENBLUM MICHAEL G [US], et al);
 [Y]US2006287509  (MARKS JAMES D [US], et al);
 [Y]  - HUSTON ET AL., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.", PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883, XP002006553

DOI:   http://dx.doi.org/10.1073/pnas.85.16.5879
 [Y]  - BIRD ET AL., "Single-Chain Antigen-Binding Proteins", SCIENCE, (1988), vol. 242, pages 423 - 426, XP000575094

DOI:   http://dx.doi.org/10.1126/science.3140379
by applicantUS4414148
 US4458066
 US4474893
 US4545985
 US4569789
 US4589071
 EP0188256
 US4659839
 US4671958
 US4680338
 US4699784
 US4894443
 US6365408
    - HROUDA ET AL., SEMIN. ONCOL., (1999), vol. 26, pages 455 - 471
    - DISIS ET AL., J. CLIN. ONCOL., (1997), vol. 15, pages 3363 - 3367
    - DRANOFF; MULLIGAN, ADV. IMMUNOL., (1995), vol. 58, pages 417 - 454
    - HURFORD ET AL., NAT. GENET., (1995), vol. 10, pages 430 - 435
    - BELARDELLI; FERRANTINI, TRENDS IMMUNOL., (2002), vol. 23, pages 201 - 208
    - SANTINI ET AL., J. EXP. MED., (2000), vol. 191, pages 1777 - 1788
    - THEOFILOPOULOS ET AL., ANNU. REV. IMMUNOL., (2005), vol. 23, pages 307 - 336
    - FINKELMAN ET AL., J. EXP. MED., (1991), vol. 174, pages 1179 - 1188
    - TOUGH ET AL., SCIENCE, (1996), vol. 272, pages 1947 - 1950
    - FERRANTINI ET AL., J. IMMUNOL., (1994), vol. 153, pages 4604 - 4615
    - GUTTERMAN ET AL., ANN. INTERN. MED., (1980), vol. 93, pages 399 - 406
    - TAKAOKA ET AL., NATURE, (2003), vol. 424, pages 516 - 523
    - SIDKY; BORDEN, CANCER RES., (1987), vol. 47, pages 5155 - 5161
    - RODRIGUEZ-VILLANUEVA; MCDONNELL, INT. J. CANCER, (1995), vol. 61, pages 110 - 11417
    - HUANG, DISSERTATION, (20060101), pages 1 - 120
    - KRANZ ET AL., PROC. NATL. ACAD. SCI., USA, (1981), vol. 78, page 5807
    - CRAGG ET AL., CURR. DIR. AUTOIMMUN., (2005), vol. 8, pages 140 - 174
    - TOBI ET AL., CANCER DETECTION AND PREVENTION, (1998), vol. 22, no. 2, pages 147 - 152
    - BORLINGHAUS ET AL., CANCER RES., (1987), vol. 47, pages 4071 - 4075
    - "Monoclonal Antibody-Toxin Conjugates: Aiming the Magic Bullet", THORPE ET AL., Monoclonal Antibodies in Clinical Medicine, ACADEMIC PRESS, (1982), pages 168 - 190
    - WALDMANN, SCIENCE, (1991), vol. 252, page 1657
    - NARANG ET AL., METH. ENZYMOL., (1979), vol. 68, pages 90 - 99
    - BROWN ET AL., METH. ENZYMOL., (1979), vol. 68, pages 109 - 151
    - BEAUCAGE ET AL., TETRA. LETT., (1981), vol. 22, pages 1859 - 1862
    - R. SCOPES, Protein Purification, SPRINGER-VERLAG, (1982), vol. 182
    - DEBINSKI ET AL., J. BIOL. CHEM., (1993), vol. 268, pages 14065 - 14070
    - KREITMAN; PASTAN, BIOCONJUG. CHEM., (1993), vol. 4, pages 581 - 585
    - BUCHNER ET AL., ANAL. BIOCHEM., (1992), vol. 205, pages 263 - 270
    - TRACY, BIOTECHNOL. PROG., (1998), vol. 14, page 108
    - JOHNSON ET AL., NATURE MED., (1996), vol. 2, page 795
    - HERBERT ET AL., PHARMACEUT. RES., (1998), vol. 15, page 357
    - DISIS, M. L.; S. M. PUPA; J. R. GRALOW; R. DITTADI; S. MENARD; M. A. CHEEVER, "High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer", J. CLIN. ONCOL., (1997), vol. 15, pages 3363 - 3367
    - DRANOFF, G.; R. C. MULLIGAN, "Gene transfer as cancer therapy", ADV. IMMUNOL., (1995), vol. 58, pages 417 - 454
    - HROUDA, D.; M. PERRY; A. G. DALGLEISH, "Gene therapy for prostate cancer", SEMIN. ONCOL., (1999), vol. 26, pages 455 - 471
    - HURFORD, R. K., JR.; G. DRANOFF; R. C. MULLIGAN; R. I. TEPPER, "Gene therapy of metastatic cancer by in vivo retroviral gene targeting", NAT. GENET., (1995), vol. 10, pages 430 - 435
    - PENG, L. S.; M. L. PENICHET; S. L. MORRISON, "A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity", J. IMMUNOL., (1999), vol. 163, pages 250 - 258
    - DELA CRUZ, J. S.; K. R. TRINH; S. L. MORRISON; M. L. PENICHET, "Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity", J IMMUNOL., (2000), vol. 165, pages 5112 - 5121
    - OSENGA, K. L.; J. A. HANK; M. R. ALBERTINI; J. GAN; A. G. STERNBERG; J. EICKHOFF; R. C. SEEGER; K. K. MATTHAY; C. P. REYNOLDS; C., "A phase I clinical trial of the hul4.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group", CLIN. CANCERRES., (2006), vol. 12, pages 1750 - 1759
    - BELARDELLI, F.; M. FERRANTINI, "Cytokines as a link between innate and adaptive antitumor immunity", TRENDS IMMUNOL., (2002), vol. 23, pages 201 - 208
    - SANTINI, S. M.; C. LAPENTA; M. LOGOZZI; S. PARLATO; M. SPADA; T. DI PUCCHIO; F. BELARDELLI, "Type I interferon as a powerful adjuvant for monocyte- derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice", J. EXP. MED., (2000), vol. 191, pages 1777 - 1788
    - THEOFILOPOULOS, A. N.; R. BACCALA; B. BEUTLER; D. H. KONO, "Type I interferons (a/p) in immunity and autoimmunity", ANNU. REV. IMMUNOL., (2005), vol. 23, pages 307 - 336
    - FINKELMAN, F. D.; A. SVETIC; I. GRESSER; C. SNAPPER; J. HOLMES; P. P. TROTTA; 1. M. KATONA; W. C. GAUSE, "Regulation by interferon - of immunoglobulin isotype selection and lymphokine production in mice", J. EXP. MED., (1991), vol. 174, pages 1179 - 1188
    - TOUGH, D. F.; P. BORROW; J. SPRENT, "Induction of bystander T cell proliferation by viruses and type I interferon in vivo", SCIENCE, (1996), vol. 272, pages 1947 - 1950
    - FERRANTINI, M.; M. GIOVARELLI; A. MODESTI; P. MUSIANI; A. MODICA; M. VENDITTI; E. PERETTI; P. L. LOLLINI; P. NANNI; G. FORNI ET AL, "IFN-a gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8- T cell-mediated tumor rejection and development of antitumor immunity: comparative studies with IFN-a-producing TS/A cells", J. IMMUNOL., (1994), vol. 153, pages 4604 - 4615
    - GUTTERMAN, J. U.; G. R. BLUMENSCHEIN; R. ALEXANIAN; H. Y. YAP; A. U. BUZDAR; F. CABANILLAS; G. N. HORTOBAGYI; E. M. HERSH; S. L. R, "Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma", ANN. INTERN. MED., (1980), vol. 93, pages 399 - 406
    - TAKAOKA, A.; S. HAYAKAWA; H. YANAI; D. STOIBER; H. NEGISHI; H. KIKUCHI; S. SASAKI; K. IMAI; T. SHIBUE; K. HONDA, "Integration of interferon- ?/? signalling to p53 responses in tumour suppression and antiviral defence", NATURE, (2003), vol. 424, pages 516 - 523
    - SIDKY, Y. A.; E. C. BORDEN, "Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses", CANCER RES., (1987), vol. 47, pages 5155 - 5161
    - RODRIGUEZ-VILLANUEVA, J.; T. J. MCDONNELL, "Induction of apoptotic cell death in non-melanoma skin cancer by interferon", INT. J. CANCER, (1995), vol. 61, pages 110 - 114
    - AKIYAMA, T.; C. SUDO; H. OGAWARA; K. TOYOSHIMA; T. YAMAMOTO, "The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity", SCIENCE, (1986), vol. 232, pages 1644 - 1646
    - BASELGA, J.; D. TRIPATHY; J. MENDELSOHN; S. BAUGHMAN; C. C. BENZ; L. DANTIS; N. T. SKLARIN; A. D. SEIDMAN; C. A. HUDIS; J. MOORE E, "Phase II study of weekly intravenous recombinant humanized anti-pl85HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer", J. CLIN. ONCOL., (1996), vol. 14, pages 737 - 744
    - SCHIER, R.; A. MCCALL; G. P. ADAMS; K. W. MARSHALL; H. MERRITT; M. YIM; R. S. CRAWFORD; L. M. WEINER; C. MARKS; J. D. MARKS, "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site", J. MOL. BIOL., (1996), vol. 263, pages 551 - 567
    - REID, T. R.; E. R. RACE; B. H. WOLFF; R. M. FRIEDMAN; T. C. MERIGAN; T. Y. BASHAM, "Enhanced in vivo therapeutic response to interferon in mice with an in vitro interferon-resistant B-cell lymphoma", CANCER RES., (1989), vol. 49, pages 4163 - 4169
    - COLOMA, M. J.; A. HASTINGS; L. A. WIMS; S. L. MORRISON, "Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction", J. IMMUNOL. METHODS, (1992), vol. 152, pages 89 - 104
    - HUANG, T. H.; S. L. MORRISON, "A trimeric anti-HER2/neu ScFv and TNF-a fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia", J. PHARMACOL. EXP. THER., (2005), vol. 316, pages 983 - 991
    - CARLSSON, G.; B. GULLBERG; L. HAFSTROM, "Estimation of liver tumor volume using different formulas: an experimental study in rats", J. CANCER RES. CLIN. ONCOL., (1983), vol. 105, pages 20 - 23
    - RAMSDEN, L.; C. C. RIDER, "Selective and differential binding of interleukin (IL)-la, IL-lp, IL-2 and IL-6 to glycosaminoglycans", EUR. J. IMMUNOL., (1992), vol. 22, pages 3027 - 3031
    - FERNANDEZ-BOTRAN, R.; J. YAN; D. E. JUSTUS, "Binding of interferon a by glycosaminoglycans: a strategy for localization and/or inhibition of its activity", CYTOKINE, (1999), vol. 11, pages 313 - 325
    - BASHAM, T. Y.; M. S. KAMINSKI; K. KITAMURA; R. LEVY; T. C. MERIGAN, "Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma", J. IMMUNOL., (1986), vol. 137, pages 3019 - 3024
    - BASHAM, T. Y.; E. R. RACE; M. J. CAMPBELL; T. R. REID; R. LEVY; T. C. MERIGAN, "Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action", J. IMMUNOL., (1988), vol. 141, pages 2855 - 2860
    - BAILON, P.; A. PALLERONI; C. A. SCHAFFER; C. L. SPENCE; W. J. FUNG; J. E. PORTER; G. K. EHRLICH; W. PAN; Z. X. XU; M. W. MODI ET A, "Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycolconjugated interferon a-2a for the treatment of hepatitis C", BIOCONJUGATE CHEM., (2001), vol. 12, pages 195 - 202
    - KOOPMAN, G.; C. P. REUTELINGSPERGER; G. A. KUIJTEN; R. M. KEEHNEN; S. T. PALS; M. H. VAN OERS, "Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis", BLOOD, (1994), vol. 84, pages 1415 - 1420
    - TIEFENBRUN, N.; D. MELAMED; N. LEVY; D. RESNITZKY; 1. HOFFMAN; S. I. REED; A. KIMCHI, "Interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible GO-like arrest", MOL. CELL. BIOL., (1996), vol. 16, pages 3934 - 3944
    - MERAZ, M. A.; J. M. WHITE; K. C. SHEEHAN; E. A. BACH; S. J. RODIG; A. S. DIGHE; D. H. KAPLAN; J. K. RILEY; A. C. GREENLUND; D. CAM, "Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway", CELL, (1996), vol. 84, pages 431 - 442
    - OKEN, M. M., "New agents for the treatment of multiple myeloma and non-Hodgkin lymphoma", CANCER, (1992), vol. 70, pages 946 - 948
    - LIU, S. J.; Y. P. SHER; C. C. TING; K. W. LIAO; C. P. YU; M. H. TAO, "Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibodyinterleukin-2 fusion proteins", BLOOD, (1998), vol. 92, pages 2103 - 2112
    - TAO, M. H.; R. LEVY, "Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma", NATURE, (1993), vol. 362, pages 755 - 758
    - HUANG, T. H.; P. Y. WU; C. N. LEE; H. 1. HUANG; S. L. HSIEH; J. KUNG; M. H. TAO, "Enhanced antitumor immunity by fusion of CTLA-4 to a self umor antigen", BLOOD, (2000), vol. 96, pages 3663 - 3670
    - HUANG, H. I.; P. Y. WU; C. Y. TEO; M. N. CHEN; Y. C. CHEN; D. SILIN; M. H. TAO, "Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand", INT. J. CANCER, (2004), vol. 108, pages 696 - 703
    - GASTL, G.; H. DENZ; C. ABBREDERIS; H. HUBER; J. TROPPMAIR; J. WIEGELE; D. NIEDERWIESER; R. FLENER; C. HUBER, "Treatment with low dose human recombinant interferon-_-2-ARG induces complete remission in patients with hairy cell leukemia", ONKOLOGIE, (1985), vol. 8, pages 143 - 144
    - ATZPODIEN, J.; H. POLIWODA; H. KIRCHNER, "Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients", SEMIN ONCOL., (1991), vol. 18, pages 108 - 112
    - KROWN, S. E.; J. PAREDES; D. BUNDOW; B. POLSKY; J. W. GOLD; N. FLOMENBERG, "Interferon--, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS clinical trials group study in patients with Kaposi's sarcoma associated with AIDS", J. CLIN. ONCOL., (1992), vol. 10, pages 1344 - 1351
    - RATH, P. C.; B. B. AGGARWAL, "Antiproliferative effects ofIFN-a correlate with the downregulation of nuclear factor- B in human Burkitt lymphoma Daudi cells", J. INTERFERON CYTOKINE RES., (2001), vol. 21, pages 523 - 528
    - YANASE, N.; K. OHSHIMA; H. IKEGAMI; J. MIZUGUCHI, "Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-a cleavage during IFN-a-induced apoptosis in Daudi B lymphoma cells", J. INTERFERON CYTOKINE RES., (2000), vol. 20, pages 1121 - 1129
    - OSHIMA, K.; N. YANASE; C. IBUKIYAMA; A. YAMASHINA; N. KAYAGAKI; H. YAGITA; J. MIZUGUCHI, "Involvement of TRAIL/TRAIL-R interaction in IFN-a-induced apoptosis of Daudi B lymphoma cells", CYTOKINE, (2001), vol. 14, pages 193 - 201
    - RILEY, J. K.; M. X. SLIWKOWSKI, "CD20: a gene in search of a function", SEMIN. ONCOL., (2000), vol. 27, pages 17 - 24
    - MCLAUGHLIN, P.; A. J. GRILLO-LOPEZ; B. K. LINK; R. LEVY; M. S. CZUCZMAN; M. E. WILLIAMS; M. R. HEYMAN; 1. BENCE-BRUCKLER; C. A. WH, "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program", J. CLIN. ONCOL., (1998), vol. 16, pages 2825 - 2833
    - SIVARAMAN, S.; P. VENUGOPAL; R. RANGANATHAN; C. G. DESHPANDE; X. HUANG; A. JAJEH; S. A. GREGORY; T. O'BRIEN; H. D. PREISLER, "Effect of interferon-a on CD20 antigen expression of B-cell chronic lymphocytic leukemia", CYTOKINES CELL MOL. THER., (2000), vol. 6, pages 81 - 87
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.